Testing a new cancer drug alone or combined with immunotherapy for advanced thyroid cancer

Plain-English translation of NCT07068542 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This trial is testing a new cancer drug called sacituzumab tirumotecan to treat three types of advanced thyroid cancer that no longer respond to standard treatments. Depending on which type of thyroid cancer you have, you may receive the medication alone or combined with an immunotherapy drug called tislelizumab. The goal is to see whether the medication can slow or stop the cancer from growing and help people live longer.

Advanced thyroid cancers that don't respond to radioactive iodine or standard targeted therapies are very difficult to treat and have limited options. This trial exists to see if this new medication can offer hope to patients who have run out of other treatment choices.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with one of three specific types of advanced thyroid cancer that cannot be surgically removed or has spread
your cancer has stopped responding to radioactive iodine treatment (if you have that type) or you have failed previous targeted therapy drugs
you have at least one measurable tumor that can be tracked on imaging scans
your overall health is stable enough to tolerate the treatment, with adequate kidney, liver, and blood cell function

You likely don't qualify if…

you have received prior treatment with similar targeted cancer drugs that work the same way
you have an active autoimmune disease requiring ongoing medication
you have untreated or unstable cancer that has spread to your brain
you have a history of serious lung inflammation or interstitial lung disease
you have had another cancer diagnosed within the past 3 years (except certain skin cancers or cervical cancer that were fully treated)

What participation looks like

You would visit the study center regularly to receive the medication by infusion into your vein. Depending on your thyroid cancer type, you may receive sacituzumab tirumotecan alone or combined with tislelizumab. Throughout the trial, you'll have blood tests, imaging scans to measure your tumors, and check-ins with doctors to monitor how well the treatment is working and watch for side effects. The study will track whether your cancer shrinks or stops growing and how long you survive.

AI-generated summary from trial data · Jun 7, 2026 · Not medical advice

Trial locations(1 site)

China

Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang